Loading
A phase 3 trial of Venetoclax, Acalabrutinib and Obinutuzumab in chronic lymphocytic leukaemia, run by AbbVie, now recruiting.
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) is a phase 3 interventional study registered as NCT06428019 by AbbVie, with 170 participants planned, started 2024-08-05 and due to reach its primary completion in 2028-03. Interventions recorded: Venetoclax, Acalabrutinib and Obinutuzumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acalabrutinib, BCL-2 inhibitors, Obinutuzumab, Chronic lymphocytic leukaemia, first treatment and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, AbbVie (incl. ImmunoGen, Capstan), Venetoclax and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax and the tag pipeline.
Shares Acalabrutinib, BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Obinutuzumab, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/